Observational studyAnnals of African medicine2026
Immunohistochemical Analysis of MUC1 and MUC4 Co-expression in Oral Leukoplakia and Oral Squamous Cell Carcinoma.
Observational study in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to evaluate the immunohistochemical co-expression of MUC1 and MUC4 in oral leukoplakia (OL) and oral squamous cell carcinoma (OSCC) and assess their potential as biomarkers for diagnosing and prognosticating oral malignancies. MATERIALS AND
methodsA retrospective observational study was conducted on formalin-fixed, paraffin-embedded tissue specimens from the archives of the Department of Oral Pathology and Microbiology. A total of 80 histopathologically confirmed cases, consisting of 40 OL and 40 OSCC cases, were selected. Immunohistochemical staining for MUC1 and MUC4 was performed using specific monoclonal antibodies, and the expression was evaluated based on localization, intensity, and extent of staining. Statistical analysis was performed using SPSS, with P < 0.05 considered statistically significant.
resultsThe study found that MUC1 and MUC4 expression were significantly higher in OSCC compared to OL. High MUC1 expression was observed in 82.5% of OSCC cases versus 30% in OL cases ( P < 0.001), and high MUC4 expression was found in 70% of OSCC cases versus 30% in OL ( P = 0.002). Co-expression of MUC1 and MUC4 was seen in 90% of OSCC cases and 65% of OL cases ( P = 0.027). Logistic regression analysis confirmed that OSCC diagnosis was a strong predictor of high MUC1 and MUC4 expression ( P < 0.001).
conclusionThe findings suggest that MUC1 and MUC4 are significantly overexpressed in OSCC compared to OL, and their co-expression may serve as a valuable biomarker combination for early diagnosis and prognosis. Elevated expression of both mucins is associated with poor prognosis, indicating their potential for use in clinical practice for risk stratification and personalized treatment in OSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.